IP Library › Granted Patent US 12,447,200
Granted Patent B2
US 12,447,200 · App. 15/442,604 · Granted Oct 21, 2025

Compositions and methods for protecting against airborne pathogens and irritants

Inventor: Nazlie Latefi (New York, NY)
Assignee: APPLIED BIOLOGICAL LABORATORIES, INC.
A61K38/47A61K9/0043A61K9/16A61K31/7012A61K31/702A61K38/1774A61K38/40A61K45/06A61K47/10A61P31/00C12Y302/01017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,447,200
App. No.
15/442,604
Granted
Oct 21, 2025
Kind
B2
Abstract

The present disclosure features methods and compositions for enhancing the ability of the respiratory membranes to filter airborne pathogens and protect a subject from respiratory infections that result from inhalation of such pathogens. In particular, the disclosure provides antimicrobial compositions that prevent and treat respiratory infections caused by bacteria, fungi, and viruses.

Claims (27)

1. A pharmaceutical composition for prophylaxis or treatment of respiratory infection comprising:

(i) soluble ICAM-1;

(ii) sialic acid;

(iii) lysozyme; and

(iv) lactoferrin; and

a pharmaceutically acceptable carrier

wherein components (i)-(iv) are present in said composition in individual form,

wherein said pharmaceutically acceptable carrier is adapted to provide a residence time of said pharmaceutical composition on the nasal and/or oral mucosa of at least 5 minutes,

the weight ratio of said component (i) to said components (iii) and (iv) active agent is about 1:100 to about 1:200 and

the weight ratio of said component (iii) to component (iv) is about 1:4 to about 1:20.

2. The pharmaceutical composition according to claim 1 , wherein said composition is in the form of a nasal spray, nasal drops, oral spray, oral rinse, or lozenge.

3. The pharmaceutical composition according to claim 1 or 2 , further comprising one or more of zinc peroxide, copper, and silver.

4. The pharmaceutical composition according to claim 1 or 2 , further comprising a neuraminidase inhibitor and/or carrageenan.

5. The pharmaceutical composition according to claim 1 or 2 , further comprising one or more of IgA, IgG, and IgM.

6. The composition according to claim 1 or 2 , further comprising one or more ingredients selected from the group consisting of marshmallow extract, calendula extract, citrus peel extract, honey extract, rosemary extract, myrrh extract, Helichrysum extract, arrowroot extract, neem oil, vitamin C, vitamin E, and grapefruit seed extract.

7. The pharmaceutical composition according to claim 4 , wherein the neuraminidase inhibitor is selected from the group consisting of quercetin, oseltamivir, zanamivir, laninamivir, and peramivir.

8. The compositions according to claim 1 or 2 , wherein said composition comprises an ICAM-1 inhibitor, and wherein said ICAM-1 inhibitor is selected from the group consisting of an anti-ICAM-1 antibody, cytokine, CD11a, ezrin (EZR), CD18, glycyrrhetinic acid, pyrrolidiniedithiocarbamate, NFKB activation inhibitor, heteryclic thiazole, lipoic acid, efalizumab, 4-[4-methylphenyl)thio]thieno92,3-c]pyridine-2-carboxamide, silibinin, stilbenes, and (+)-epigalloyl-catechin-gallate [(+)-EGCG].

9. The composition according to claim 1 or 2 , wherein the composition is formulated as a microsphere.

10. The pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier is adapted to provide a residence time of said pharmaceutical composition on the nasal and/or oral mucosa of at least 30 minutes.

11. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises from about 0.0000001% to 0.1% soluble ICAM-1 by weight of the composition.

12. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises from about 0.000001% to 0.01% soluble ICAM-1 by weight of the composition.

13. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises from about 0.0000001-1.0% soluble lactoferrin by weight of the composition.

14. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises from about 0.000001-1.0% lysozyme by weight of the composition.

15. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises

from about 0.000001% to 0.01% soluble ICAM- 1 by weight of the composition,

from about 0.0000001-1.0% soluble lactoferrin by weight of the composition, and

from about 0.000001-1.0% lysozyme by weight of the composition.

Assignments (3)
SECURITY INTEREST Recorded Mar 4, 2026
From: APPLIED BIOLOGICAL LABORATORIES INC.
To: TRANSMINEO LLC
Reel/Frame 074779/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2024
From: LATEFI, NAZLIE, MRS.
To: APPLIED BIOLOGICAL LABORATORIES, INC.
Reel/Frame 068129/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2017
From: LATEFI, NAZLIE
To: APPLIED BIOLOGICAL LABORATORIES, INC.
Reel/Frame 043988/0307 →
Continuity (2)
Provisional Application 62299775 · Feb 25, 2016
Related Publication 20170246262A1 · Aug 31, 2017
References Cited (108)
US 2156254A · Manchey · 1939 [cited by examiner]
US 4734279A · Wolfgang et al. · 1988 [cited by applicant]
US 5576299A · Ando et al. · 1996 [cited by applicant]
US 5993809A · Weaver et al. · 1999 [cited by applicant]
US 6017880A · Eisenberg et al. · 2000 [cited by applicant]
US 6020333A · Berque · 2000 [cited by applicant]
US 6093417A · Petrus · 2000 [cited by examiner]
US 6183742B1 · Kiczka · 2001 [cited by applicant]
US 6329339B1 · Pompei et al. · 2001 [cited by applicant]
US 6365156B1 · Lee · 2002 [cited by examiner]
US 6503881B2 · Krieger et al. · 2003 [cited by applicant]
US 6716813B2 · Lim et al. · 2004 [cited by applicant]
US 7459283B2 · Wertz et al. · 2008 [cited by applicant]
US 7662607B2 · Wang et al. · 2010 [cited by applicant]
US 7846430B2 · Ferrari · 2010 [cited by applicant]
US 7989003B2 · Hensley et al. · 2011 [cited by applicant]
US 8263138B2 · Perraudin · 2012 [cited by applicant]
US 20010006939A1 · Niven · 2001 [cited by applicant]
US 20030134779A1 · Diarra et al. · 2003 [cited by applicant]
US 20030219402A1 · Rutter · 2003 [cited by examiner]
US 20040248825A1 · McCullers · 2004 [cited by applicant]
US 20050158327A1 · Mohapatra et al. · 2005 [cited by applicant]
US 20050245467A1 · Berg · 2005 [cited by examiner]
US 20060159671A1 · Fischetti · 2006 [cited by applicant]
US 20070099855A1 · Cinatl · 2007 [cited by applicant]
US 20070116750A1 · Wolcott · 2007 [cited by applicant]
US 20090142298A1 · Shatunovskiy · 2009 [cited by applicant]
US 20090317378A1 · Perraudin · 2009 [cited by applicant]
US 20100143490A1 · Roberts et al. · 2010 [cited by applicant]
US 20100160245A1 · Lines · 2010 [cited by applicant]
US 20100209419A1 · Bhushan · 2010 [cited by examiner]
US 20100233129A1 · Fichot · 2010 [cited by examiner]
US 20110015120A1 · Bortolin · 2011 [cited by applicant]
US 20110052727A1 · Polansky · 2011 [cited by applicant]
US 20110059919A1 · Grassauer et al. · 2011 [cited by applicant]
US 20110301077A1 · Perraudin · 2011 [cited by applicant]
US 20120171164A1 · Wittke et al. · 2012 [cited by applicant]
US 20120308579A1 · Tobin · 2012 [cited by applicant]
US 20130034542A1 · Ganter et al. · 2013 [cited by applicant]
US 20130058912A1 · Griswold et al. · 2013 [cited by applicant]
US 20130309220A1 · Matalon · 2013 [cited by applicant]
US 20140121237A1 · Tripp · 2014 [cited by applicant]
US 20150093371A1 · Colman · 2015 [cited by examiner]
US 20160022713A1 · Wang · 2016 [cited by applicant]
US 20160144004A1 · Pellico · 2016 [cited by applicant]
US 20170065720A1 · Nguyen et al. · 2017 [cited by applicant]
CN 1248603A · 2000 [cited by applicant]
CN 101190331A · 2008 [cited by applicant]
CN 100493605C · 2009 [cited by applicant]
CN 101507748A · 2009 [cited by applicant]
CN 101947278A · 2011 [cited by applicant]
CN 101966285B · 2013 [cited by applicant]
EP 2845606A1 · 2015 [cited by applicant]
GB 981260A · 1965 [cited by applicant]
GB 1171183A · 1969 [cited by applicant]
GB 1174187A · 1969 [cited by applicant]
GB 1431709 · 1976 [cited by applicant]
GB 2374008A · 2002 [cited by applicant]
GB 2374008B · 2002 [cited by applicant]
JP 2001525814A · 2001 [cited by applicant]
JP 2013515022A · 2013 [cited by applicant]
KR 101119538B1 · 2012 [cited by applicant]
KR 20120065654A · 2012 [cited by applicant]
RU 2504396C1 · 2014 [cited by applicant]
RU 2535053C2 · 2014 [cited by applicant]
RU 2548803C2 · 2015 [cited by applicant]
WO 09527736A1 · 1995 [cited by applicant]
WO 1998006425A1 · 1998 [cited by applicant]
WO 0012081A1 · 2000 [cited by applicant]
WO 2001092336A1 · 2001 [cited by applicant]
WO 03051281A1 · 2003 [cited by applicant]
WO 2004024919A1 · 2004 [cited by applicant]
WO 2006028497A2 · 2006 [cited by applicant]
WO 201107367A2 · 2011 [cited by applicant]
WO 2011130799A1 · 2011 [cited by applicant]
WO 2012022734A2 · 2012 [cited by applicant]
WO 2014151523A1 · 2014 [cited by applicant]
WO 2015092047A2 · 2015 [cited by applicant]
Stoppler, M. C. (obtained online via www.medicinenet.com on Jun. 29, 2018): p. 1-5 (Year: 2018). [cited by examiner]
Carvalho et al. (Abstract—44th Annual Meeting of the Brazilian Society for Biochemistry and Molecular Biology, Aug. 2015, p. 1 (Year: 2015) (Year: 2015). [cited by examiner]
Greve et al. (Journal of Virology, Nov. 1991. p. 6015-6023). (Year: 1991) (Year: 1991). [cited by examiner]
Ronald J. Tallarida, Quantitative Methods for Assessing Drug Synergism, 2 Genes & Cancer 1003 (Year: 2011). [cited by examiner]
Antonio Pellegrini & Monika Engels, Antiviral Compounds Derived from Naturally Occurring Proteins, 4 Curr. Med. Chem.—Anti-Infective Agents, 55 (Year: 2005). [cited by examiner]
G. Lampis, et al, Enhancement of Anti-Herpetic Activity of Glycyrrhizic Acid by Physiological Proteins, 12 Antivir. Chenm. Chemother. 125 (Year: 2001). [cited by examiner]
Saad et al., “Effects of bovine colostrum on recurrent respiratory tract infections and diarrhea in children,” Medicine, vol. 95, issue 37, pp. 1-5 (2016). [cited by applicant]
Wakabayashi et al., “Lactoferrin for prevention of common viral infections,” Journal of Infection and Chemotherapy, Aug. 30, 2014, vol. 20, 666-671. [cited by applicant]
Al-Nabulsi et al., “Enhancing the antimicrobial effects of bovine lactoferrin against [cited by applicant]
Davis et al., “Quercetin reduces susceptibility to influenza infection following stressful exercise,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, Aug. 1, 2008, vol. 295 R505-R509. [cited by applicant]
Kim et al., Inhibition of influenza virus replication by plant-derived isoquercetin, Antiviral Research, Aug. 31, 2010, vol. 88, 227-235. [cited by applicant]
International Preliminary Report on Patentability to corresponding International Application No. PCT/US2017/019535 mailed Sep. 7, 2018 (10 pages). [cited by applicant]
Abouhmad et al., “T4 lysozyme fused with cellulos-binding module for antimicrobial cellulosic wound dressing materials,” Journal of Applied Microbiology, vol. 121, pp. 115-125 (2016). [cited by applicant]
International Search Report and Written Opinion to corresponding International Application No. PCT/US2017/019535 mailed May 8, 2017 (12 pages). [cited by applicant]
Lei et al., “Dynamic Spongy Microporous Films to Load Lysozyme for Antibacterial Coating,” Acta Polymerica Sinica, No. 5, pp. 744-751 (2017). [cited by applicant]
Marlin et al., “A Soluble Form of Intercellular Adhesion Molecule-1 Inhibits Rhinovirus Infection,” Nature; London, vol. 344, No. 6261, pp. 70-72 (1990). [cited by applicant]
Muscedere et al., “Prevention of nosocomial infections in critically ill patients with lactoferrin (PREVAIL study): study protocol for a randomized controlled trial,” Trials, vol. 17, No. 474 (2016). [cited by applicant]
Pammi et al., “Oral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates (Review),” Issue 10, 14 pages (2011). [cited by applicant]
Samaranayake et al., “Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces,” ScienceDirect, vol. 54, pp. 115-126 (2009). [cited by applicant]
Turner et al., “Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection: A randomized Clinical Trial,” JAMA, May 19, 1999, vol. 281, No. 19, pp. 1797-1804. [cited by applicant]
Search Report and Written Opinion in corresponding Singapore Patent Application No. 11201806868T, dated Nov. 28, 2019 (13 pages). [cited by applicant]
Search Report for corresponding Russian Patent Application No. 2018133581 (2 pages). [cited by applicant]
Office Action for corresponding Russian Patent Application No. 2018133581, issued on Aug. 11, 2020 (5 pages). [cited by applicant]
Yulish, et al., “Factors of immunity in respiratory infections and methods for their activating in aid of a pediatrist,” 2010, vol. 5, No. 6, pp. 63-67 (English Abstract). [cited by applicant]
Communication Pursuant to Article 94(3) in Corresponding EP App No. 17757390.4, issued Mar. 16, 2021. [cited by applicant]
Koenighofer et al., “Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials”, Multidisciplinary Respiratory Medicine, Biomed Central Ltd, London, UK,… [cited by applicant]
Jefferson et al., “Advances in the diagnosis and management of influenza”, Current Infectious Disease Reports, Current Science, Philadelphia, PA, US, vol. 4, No. 3, May 1, 2002 (May 1, 2002), pp. 206-210. [cited by applicant]
First Examination Report for corresponding Indian Application No. 201817032360, dated Jun. 25, 2020 (6 pages). [cited by applicant]
European Search Report from corresponding EP AppIn No. 18849807.5, mailed May 17, 2021. [cited by applicant]
Office action from corresponding Brazilian Application No. BR112018067914-3 mailed Mar. 26, 2021. [cited by applicant]